Corresponding Author: Brian L. Pearlman, MD, Wellstar Atlanta Medical Center, Center for Hepatitis C, 285 Boulevard NE, Ste 525, Atlanta, GA 30312 (Brianpearlman3@hotmail.com).
Published Online: June 13, 2022. doi:10.1001/jama.2022.8384
Conflict of Interest Disclosures: Dr Pearlman reported serving on the speakers bureau and an advisory board of Gilead Sciences for viral hepatitis–related topics. Gilead has a nonapproved medication in clinical trials for delta hepatitis.
Additional Contributions: We thank the patient for providing permission to share her information.
5.Brancaccio
G , Fasano
M , Grossi
A , Santantonio
TA , Gaeta
GB . Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir.
Aliment Pharmacol Ther. 2019;49(8):1071-1076. doi:
10.1111/apt.15188PubMedGoogle ScholarCrossref